SYGNIS announces the adaptation of its organisation to the new business activity

03-Jan-2013 - Germany

SYGNIS Pharma announced the discontinuation of its therapeutic R&D project KIBRA and the adaptation of its organisation to the new business activity. At the Heidelberg site the staff will be reduced by 10 employees.

These measures are implemented to concentrate the financial resources on the development and marketing of novel technologies in molecular biology in line with the new corporate strategy. This new business was acquired in 2012 by joining forces with the Spanish X-Pol Biotech.

Other news from the department business & finance

More news from our other portals

All FT-IR spectrometer manufacturers at a glance